News

Unichem Laboratories sale its stake in Optimus Drugs

The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.

The sale of 19.97% equity shares of Unichem Laboratories Limited in Optimus Drugs Private Limited to Sekhmet Pharmaventures Private Limited was completed on September 22, 2022

The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.

Upcoming E-conference

Other Related stories

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

Interviews

Capex comm

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Our focus

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

We have co

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

Appointments

Gland Pharma appoints Satnam Singh Loomba as COO

Gland Pharma appoints Satnam Singh Loomba as COO

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

Startup

Pfizer joins hands with NIPER (Ahmedabad) to support Healthcare Innovation in India

Pfizer joins hands with NIPER (Ahmedabad) to support Healthcare Innovation in India

DPIIT recognises 1, 17,254 startups as on Dec 2023

DPIIT recognises 1, 17,254 startups as on Dec 2023

SigTuple’s AI100 with Shonit receives USFDA 510(k) clearance

SigTuple’s AI100 with Shonit receives USFDA 510(k) clearance

Digitization

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients

Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome

Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome

Latest Stories

FDA grants full approval for TIVDAK to treat cervical cancer

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Opinion

Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals

Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals

Advanced Treatments for Brain Tumors: Secure Procedures Available

Advanced Treatments for Brain Tumors: Secure Procedures Available

Interviews

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

Vinod Paremal President & MD, Evonik, India Region

Packaging

Sulzer launches new biodegradable polymer

Sulzer launches new biodegradable polymer

Solvay launches new PVDC coating solution for more sustainable pharma blister films

Solvay launches new PVDC coating solution for more sustainable pharma blister films

PCI Pharma plans Biologics assembly facility in the Midwest

PCI Pharma plans Biologics assembly facility in the Midwest